# [DISCUSSION DRAFT]

118TH CONGRESS
1ST SESSION

# H. R. _____

To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

---

IN THE HOUSE OF REPRESENTATIVES

M__. _____ introduced the following bill; which was referred to the Committee on _____

---

# A BILL

To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.

*Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,*

**SECTION 1. SHORT TITLE.**

This Act may be cited as the "**[**_____**]**".

**SEC. 2. REVIEWING THE SCHEDULING OF BUPRENORPHINE-NALOXONE COMBINATION PRODUCTS.**

(a) SECRETARY OF HHS.—The Secretary of Health and Human Services shall—

(1) review and, as appropriate, update the scientific and medical evaluation conducted under section 201(b) of the Controlled Substance Act (21 U.S.C. 811(b)) with respect to buprenorphine-naloxone combination products; and

(2) update, as necessary, the Secretary's scheduling recommendation under such section with respect to such products.

(b) ATTORNEY GENERAL.—The Attorney General shall—

(1) review the recommendations provided by the Secretary under subsection (a), and all other relevant data with respect to the scheduling of buprenorphine-naloxone combination products;

(2) consider the factors listed in subsection (c) of section 201 of the Controlled Substance Act (21 U.S.C. 811) with respect to such products; and

(3) consistent with such section 201, make such scheduling changes with respect to such products as the Secretary may determine appropriate.